NASDAQ:EYPT - Eyepoint Pharmaceuticals Stock Price, Forecast & News

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) issued its earnings results on Thursday, November, 7th. The company reported ($0.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.01. The business had revenue of $2.51 million for the quarter, compared to analyst estimates of $4.81 million. Eyepoint Pharmaceuticals had a negative return on equity of 250.32% and a negative net margin of 409.07%. View Eyepoint Pharmaceuticals' Earnings History.

Eyepoint Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eyepoint Pharmaceuticals.

Eyepoint Pharmaceuticals updated its FY 2019 Pre-Market earnings guidance on Thursday, January, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.3-20 million, compared to the consensus revenue estimate of $17.9 million.

4 brokerages have issued 12 month price objectives for Eyepoint Pharmaceuticals' shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Eyepoint Pharmaceuticals' stock price to reach $4.38 in the next twelve months. This suggests a possible upside of 124.4% from the stock's current price. View Analyst Price Targets for Eyepoint Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyepoint Pharmaceuticals.

Media stories about EYPT stock have been trending somewhat negative on Monday, according to InfoTrie. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eyepoint Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Eyepoint Pharmaceuticals.

Eyepoint Pharmaceuticals saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 8,490,000 shares, a decrease of 5.5% from the December 15th total of 8,980,000 shares. Based on an average daily trading volume, of 570,600 shares, the days-to-cover ratio is currently 14.9 days. Approximately 13.0% of the company's stock are sold short. View Eyepoint Pharmaceuticals' Current Options Chain.

Some companies that are related to Eyepoint Pharmaceuticals include Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Precipio (PRPO), Scientific Industries (SCND), Aethlon Medical (AEMD), Pressure Biosciences (PBIO) and PositiveID (PSID).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyepoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), XOMA (XOMA), Opko Health (OPK), Catalyst Pharmaceuticals (CPRX), AcelRx Pharmaceuticals (ACRX), Alimera Sciences (ALIM), Novavax (NVAX) and BIOLINERX LTD/S (BLRX).

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EYPT stock can currently be purchased for approximately $1.95.

Eyepoint Pharmaceuticals has a market capitalization of $210.83 million and generates $2.96 million in revenue each year. The company earns $-53,170,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe.View Additional Information About Eyepoint Pharmaceuticals.

The official website for Eyepoint Pharmaceuticals is http://eyepointpharma.com/.

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 833-393-7646 or via email at [email protected]